Repligen: resin recovery feature a ‘differentiator’ in chromatography space

By Dan Stanton

- Last updated on GMT

The OPUS R resin unpacking port. Image: c/o Repligen
The OPUS R resin unpacking port. Image: c/o Repligen

Related tags Chromatography Revenue

A resin recovery feature being added to its larger prefilled chromatography columns offers an ‘insurance policy’ for drugmakers, says Repligen.

Bioprocessing technology and Protein A ligand supplier Repligen published its third quarter 2016 financials last week, and reported a 25% y-o-y rise in product revenue to $24.7m, attributed in part to sales of its OPUS-branded chromatography columns.

And sales of the prefilled offering are expected to continue to rise, the firm said, driven by a new resin recovery feature on its 45cm and 60cm which - according to spokeswoman Sondra Newman - positions Repligen alone amongst the main chromatography tech vendors.

“OPUS R columns feature a side port through which chromatography resins can be removed, following a defined protocol,”​ she told Biopharma-Reporter, adding the feature serves two main purposes.

“As an insurance policy to lower risk in the event of any process deviations - for example, accidental over pressurizing a column – [and it] gives flexibility to the end user to use resin after a campaign is finished for engineering, scale down and reuse of studies in process development.”

Her comments echoed CEO’s Tony Hunt who described the feature as “a differentiator in the whole pre-packing space”​ during a conference call last week. However, he also told stakeholders there will be a price increase associated with the new feature.

But according to Newman “the price increase will be nominal. The strategy with OPUS R is more focused on providing an important differentiator that our customers have been asking for.”

The feature – which was first launched at Biotech Week in Boston last month​ – will be standard on the two larger diameter Opus columns, as these represent where the resin investment is most significant, and will be implanted by the second quarter 2017.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more